menu search

Praxis Precision Medicines Announces Closing of Financing and Reiterates Corporate Priorities

Praxis Precision Medicines Announces Closing of Financing and Reiterates Corporate Priorities
Strong demand for financing including full exercise of overallotment option with net proceeds of $63.3 million Cash runway extended into Q1 2025 Phase 2 Photoparoxsymal Response (PPR) study to evaluate PRAX-628 expected to read-out by YE 2023 Plan to begin ulixacaltamide Phase 3 enrollment in Q4 2023 to support a 2025 NDA filing BOSTON, June […] The post Praxis Precision Medicines Announces Closing of Financing and Reiterates Corporate Priorities appeared first on ForexTV... Read More
Posted: Jun 22 2023, 11:00
Author Name: forextv
Views: 081117

Search within

Pages Search Results: